...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
【24h】

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience

机译：MRCC患者的一线Pazopanib治疗的长期反应：多中心的意大利经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Patients and Methods: Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for 12 months in the first-line setting. Results: In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI=20.2-25.0). Eighty-three patients (74.1%) had a PFS = 18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3 .05; p=0.04). Conclusion: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.
机译：背景/目的：最有可能受益于Pazopanib疗法的患者的具体特征仍然不确定。 我们报告了意大利多中心的结果，回顾性分析调查与转移肾细胞癌患者对第一线Pazopanib的更长响应相关的因素。 患者和方法：如果他们接受了用Pazopanib（800mg /天）的治疗，则考虑成年患者。在一线设置中12个月。 结果：共有112名患者进行评估。 标准帕替尼人的中位数持续时间为22.6个月（IQR 17.8个月）。 中位数PFS为22.6个月（95％CI = 20.2-25.0）。 八十三名患者（74.1％）具有PFS＆ = 18个月。 中位数OS为32.9个月（95％CI = 30.2-35.6）。 在统计分析时，只有PS得分（1+与0）与PFS显着相关（HR = 1.76; 95％CI = 1.02-3 .05; P = 0.04）。 结论：Pazopanib治疗可能适用于MRCC的所有患者，特别是在PS 0中的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号